Sai Life Sciences to open discovery biology facility at R&D campus

The company's client base works across a set of therapeutic areas including oncology, CNS, antivirals, and inflammation

Sai Life Sciences, a global CDMO, has announced the opening of a discovery biology facility at its integrated R&D campus in Hyderabad, India.

CEO & MD of Sai Life Sciences, Krishna Kanumuri said: "The new facility marks the culmination of a journey we began two years ago, of creating differentiated value for our discovery clients through an integrated delivery model across Boston and Hyderabad. By bringing the best of talent, technology, complementary services and efficiency we are confident of bringing unique value to our clients and are keen to take on integrated discovery mandates, at scale."

The company employs what it calls an integrated delivery model

The facility houses expanded in vitro and in vivo biology services, DMPK, toxicology and a vivarium. It augments the company’s capabilities and capacity to deploy platforms and technologies for accelerating integrated drug discovery programmes.

The company has been growing its biology capabilities to complement its foundation in medicinal chemistry, DMPK and toxicology for supporting its customers across the entire drug discovery journey from target ID and validation to IND. In 2019, the company opened its first international R&D facility with a biology lab in Boston, USA, designed to offer start-up and biotech companies in the region services to address exploratory and custom biology needs.

The company employs what it calls an integrated delivery model, whereby critical exploratory work involving close hand-in-hand collaboration with clients is done at the Boston lab, following which, established assays are tech transferred to Hyderabad for greater throughput. The technology transfer is achieved through global organisation and matching infrastructure across both sites.

The company's client base works across a set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others, and has advanced 35+ programmes to different clinical phases (IND to Phase-III).

Companies